Federated Hermes’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.4K | Buy |
170
+2
| +1% | +$200 | ﹤0.01% | 1796 |
|
|
2025
Q4 | $16.3K | Buy |
168
+79
| +89% | +$6.78K | ﹤0.01% | 1787 |
|
|
2025
Q3 | $6.33K | Buy |
89
+28
| +46% | +$1.87K | ﹤0.01% | 1922 |
|
|
2025
Q2 | $3.65K | Hold |
61
| – | – | ﹤0.01% | 1916 |
|
|
2025
Q1 | $3.2K | Hold |
61
| – | – | ﹤0.01% | 1916 |
|
|
2024
Q4 | $3.35K | Sell |
61
-2
| -3% | -$105 | ﹤0.01% | 1932 |
|
|
2024
Q3 | $3.17K | Hold |
63
| – | – | ﹤0.01% | 1904 |
|
|
2024
Q2 | $2.77K | Sell |
63
-55
| -47% | -$2.34K | ﹤0.01% | 1885 |
|
|
2024
Q1 | $5.19K | Sell |
118
-294
| -71% | -$13K | ﹤0.01% | 1834 |
|
|
2023
Q4 | $19.6K | Buy |
412
+6
| +1% | +$252 | ﹤0.01% | 1749 |
|
|
2023
Q3 | $18K | Sell |
406
-6
| -1% | -$279 | ﹤0.01% | 1775 |
|
|
2023
Q2 | $19.7K | Hold |
412
| – | – | ﹤0.01% | 1778 |
|
|
2023
Q1 | $16.2K | Hold |
412
| – | – | ﹤0.01% | 1831 |
|
|
2022
Q4 | $11.7K | Sell |
412
-147
| -26% | -$4.21K | ﹤0.01% | 1852 |
|
|
2022
Q3 | $17K | Hold |
559
| – | – | ﹤0.01% | 1782 |
|
|
2022
Q2 | $19K | Sell |
559
-46
| -8% | -$1.65K | ﹤0.01% | 1773 |
|
|
2022
Q1 | $27K | Buy |
605
+6
| +1% | +$277 | ﹤0.01% | 1801 |
|
|
2021
Q4 | $28K | Sell |
599
-26
| -4% | -$1.05K | ﹤0.01% | 1850 |
|
|
2021
Q3 | $21K | Buy |
625
+6
| +1% | +$204 | ﹤0.01% | 1932 |
|
|
2021
Q2 | $18K | Sell |
619
-6
| -1% | -$165 | ﹤0.01% | 1932 |
|
|
2021
Q1 | $16K | Hold |
625
| – | – | ﹤0.01% | 1972 |
|
|
2020
Q4 | $14K | Sell |
625
-111
| -15% | -$2.56K | ﹤0.01% | 1938 |
|
|
2020
Q3 | $16K | Buy |
736
+11
| +2% | +$247 | ﹤0.01% | 1921 |
|
|
2020
Q2 | $17K | Sell |
725
-177
| -20% | -$3.8K | ﹤0.01% | 1886 |
|
|
2020
Q1 | $19K | Sell |
902
-120
| -12% | -$2.86K | ﹤0.01% | 1797 |
|
|
2019
Q4 | $24K | Sell |
1,022
-426
| -29% | -$9.95K | ﹤0.01% | 1814 |
|
|
2019
Q3 | $30K | Sell |
1,448
-106
| -7% | -$2.16K | ﹤0.01% | 1785 |
|
|
2019
Q2 | $32K | Sell |
1,554
-643
| -29% | -$15.1K | ﹤0.01% | 1736 |
|
|
2019
Q1 | $62K | Sell |
2,197
-1,740
| -44% | -$45.5K | ﹤0.01% | 1635 |
|
|
2018
Q4 | $96K | Sell |
3,937
-2,234
| -36% | -$60K | ﹤0.01% | 1619 |
|
|
2018
Q3 | $229K | Sell |
6,171
-707
| -10% | -$19.1K | ﹤0.01% | 1590 |
|
|
2018
Q2 | $143K | Buy |
6,878
+63
| +0.9% | +$1.11K | ﹤0.01% | 1578 |
|
|
2018
Q1 | $96K | Sell |
6,815
-33,174
| -83% | -$472K | ﹤0.01% | 1597 |
|
|
2017
Q4 | $606K | Buy |
39,989
+383
| +1% | +$4.87K | ﹤0.01% | 1342 |
|
|
2017
Q3 | $380K | Sell |
39,606
-794
| -2% | -$7.53K | ﹤0.01% | 1412 |
|
|
2017
Q2 | $347K | Buy |
40,400
+2,807
| +7% | +$24K | ﹤0.01% | 1453 |
|
|
2017
Q1 | $335K | Buy |
37,593
+9,394
| +33% | +$87.1K | ﹤0.01% | 1419 |
|
|
2016
Q4 | $313K | Buy |
28,199
+14,139
| +101% | +$152K | ﹤0.01% | 1425 |
|
|
2016
Q3 | $239K | Buy |
14,060
+86
| +0.6% | +$1.59K | ﹤0.01% | 1447 |
|
|
2016
Q2 | $304K | Sell |
13,974
-99
| -0.7% | -$1.78K | ﹤0.01% | 1399 |
|
|
2016
Q1 | $270K | Sell |
14,073
-4,079
| -22% | -$78.1K | ﹤0.01% | 1431 |
|
|
2015
Q4 | $509K | Buy |
18,152
+8,775
| +94% | +$248K | ﹤0.01% | 1287 |
|
|
2015
Q3 | $228K | Buy |
+9,377
| New | +$224K | ﹤0.01% | 1479 |
|
Other funds holding IRMD
CCM
VCM
NTCM
Federated Hermes's IRMD Position: Q1 2026 in Review
Federated Hermes increased its iRadimed (IRMD) stake by 1.2% in Q1 2026, buying an estimated $200 and bringing the position to 170 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1796.
Federated Hermes first reported a position in IRMD in Q3 2015 and has held it in 43 quarters since. The position peaked at $606K in Q4 2017. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Federated Hermes held 170 shares of iRadimed worth $16.4K as of Q1 2026.
- Federated Hermes bought 2 iRadimed shares in Q1 2026, an estimated $200.
- iRadimed made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1796 holding.
- Federated Hermes first reported a position in iRadimed in Q3 2015 and has held it in 43 quarters since.
- Federated Hermes's iRadimed position peaked at $606K in Q4 2017.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.